BACKGROUND: Clostridium difficile infections are becoming more common, more severe, and more likely to recur. Conventional treatment with antibiotics often fails to eradicate the infection; even when it succeeds, recurrent infection is common. Complementary treatment with probiotic agents to reconstitute the physiological intestinal flora does not yield any consistent benefit. In recent years, fecal transplantation has been used in the English-speaking countries with cure rates of about 87%, but the available evidence is limited to large case series. No randomized controlled trials have been performed. We present the case of a 73-year-old woman with intractable, recurrent enterocolitis due to Clostridium difficile who was successfully treated with fecal transplantation via colonoscopy. CASE DESCRIPTION: Upon the completion of antibiotic treatment for a second recurrence of enterocolitis, stool in liquid suspension was introduced into the patient's colon through a colonoscope. Prior testing had shown the stool donor to be free of acute infection or stool pathogens. The patient was given loperamide to prolong contact of the stool transplant with the colonic mucosa. She was also treated with Saccharomyces cerevisiae for four weeks. COURSE: There was no clinical or microbiological evidence of a further recurrence of enterocolitis for 6 months after transplantation. Stool transplantation had no adverse effects. CONCLUSION: This patient had a lasting remission of enterocolitis due to Clostridium difficile after the treatment described above. Fecal transplantation seems to be a safe and highly effective treatment for recurrent Clostridium difficile infection. It is unclear whether the administration of Saccharomyces cerevisiae confers any additional benefit.
BACKGROUND:Clostridium difficileinfections are becoming more common, more severe, and more likely to recur. Conventional treatment with antibiotics often fails to eradicate the infection; even when it succeeds, recurrent infection is common. Complementary treatment with probiotic agents to reconstitute the physiological intestinal flora does not yield any consistent benefit. In recent years, fecal transplantation has been used in the English-speaking countries with cure rates of about 87%, but the available evidence is limited to large case series. No randomized controlled trials have been performed. We present the case of a 73-year-old woman with intractable, recurrent enterocolitis due to Clostridium difficile who was successfully treated with fecal transplantation via colonoscopy. CASE DESCRIPTION: Upon the completion of antibiotic treatment for a second recurrence of enterocolitis, stool in liquid suspension was introduced into the patient's colon through a colonoscope. Prior testing had shown the stool donor to be free of acute infection or stool pathogens. The patient was given loperamide to prolong contact of the stool transplant with the colonic mucosa. She was also treated with Saccharomyces cerevisiae for four weeks. COURSE: There was no clinical or microbiological evidence of a further recurrence of enterocolitis for 6 months after transplantation. Stool transplantation had no adverse effects. CONCLUSION: This patient had a lasting remission of enterocolitis due to Clostridium difficile after the treatment described above. Fecal transplantation seems to be a safe and highly effective treatment for recurrent Clostridium difficileinfection. It is unclear whether the administration of Saccharomyces cerevisiae confers any additional benefit.
Authors: Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue Journal: N Engl J Med Date: 2011-02-03 Impact factor: 91.245
Authors: J Landy; H O Al-Hassi; S D McLaughlin; A W Walker; P J Ciclitira; R J Nicholls; S K Clark; A L Hart Journal: Aliment Pharmacol Ther Date: 2011-06-20 Impact factor: 8.171
Authors: Martijn P Bauer; Daan W Notermans; Birgit H B van Benthem; Jon S Brazier; Mark H Wilcox; Maja Rupnik; Dominique L Monnet; Jaap T van Dissel; Ed J Kuijper Journal: Lancet Date: 2011-01-01 Impact factor: 79.321
Authors: Martin H Floch; W Allan Walker; Karen Madsen; Mary Ellen Sanders; George T Macfarlane; Harry J Flint; Levinus A Dieleman; Yehuda Ringel; Stefano Guandalini; Ciaran P Kelly; Lawrence J Brandt Journal: J Clin Gastroenterol Date: 2011-11 Impact factor: 3.062
Authors: Stefan Hagel; Anne Fischer; Philipp Ehlermann; Thorsten Frank; Kester Tueffers; Andreas Sturm; Alexander Link; Muenevver Demir; Arno Siebenhaar; Martin Storr; Thomas Glueck; Erhard Siegel; Philip Solbach; Felix Goeser; Christian B. Koelbel; Ansgar Lohse; Christoph Luebbert; Ulrich Kandzi; Matthias Maier; Stefanie Schuerle; Markus M. Lerch; Daniela Tacke; Oliver A. Cornely; Andreas Stallmach; Maria Vehreschild Journal: Dtsch Arztebl Int Date: 2016-09-05 Impact factor: 5.594